Oramed Pharmaceuticals, Inc. Stock OTC Bulletin Board
Equities
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 15 | Compugen Names David Silberman CFO | MT |
May. 09 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 1.5M | Sales 2025 * | 4M | Capitalization | 95.07M |
---|---|---|---|---|---|
Net income 2024 * | -4M | Net income 2025 * | -14M | EV / Sales 2024 * | 63.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 23.8 x |
P/E ratio 2024 * |
-23.4
x | P/E ratio 2025 * |
-6.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.73% |
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13-04-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.72% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |